Immunosuppression, a double-edged sword: sepsis, skin cancer risk, and potential Multiple Sclerosis stabilization

Simple item page
dc.contributor.authorMull, Mihikaen
dc.contributor.authorSingh, Ileeshaen
dc.contributor.editorMehta, Shobhaen
dc.contributor.editorCronin, Pádraigen
dc.date.accessioned2025-10-28T13:55:07Z
dc.date.available2025-10-28T13:55:07Z
dc.date.issued2025en
dc.description.abstractBackground: Immunosuppression remains an essential component in post-transplant care but carries significant risks, including infection and malignancy. However, post-transplant immunosuppressants may have a role in stabilising multiple sclerosis (MS), despite not being first-line therapy. Case Presentation: A 65-year-old female with a history of autosomal dominant polycystic kidney disease and associated polycystic liver disease underwent a deceased-donor renal transplant in 1998. Her long-term maintenance immunosuppressive regimen included tacrolimus, low-dose prednisolone, and azathioprine (discontinued in 2024). She was diagnosed with MS in 1990. In July 2024, she was hospitalised for sepsis, with an enhancing hepatic cyst being the presumed source. Blood cultures grew Enterococcus faecium, which was treated with IV vancomycin. This occured on the background of recurrent gram-negative bacteraemias and non-melanoma skin cancers since 2020. These complications were attributed to long-term immunosuppression. Nonetheless, her MS has remained clinically stable for over 20 years. She reported no relapses or neurological deficits, and an MRI in September 2024 showed no new demyelinating lesions. Discussion: This case highlights the double-edged nature of immunosuppressive therapy. While tacrolimus and azathioprine are associated with increased risk of infections and malignancies, particularly skin cancers, they may also modulate autoimmune neuroinflammation. Although evidence for tacrolimus use in MS treatment remains limited, some studies suggest possible neuroprotective effects. Conversely, while azathioprine has shown potential benefits in relapse reduction in controlled trials, further research is needed to establish its full utility in MS management. Short-term high-dose prednisolone is effective in acute exacerbations but lacks evidence for long-term MS stabilisation. Conclusion: This is a unique caseen
dc.description.statusNot peer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationMull, M. and |Singh, I. (2025) 'Immunosuppression, a double-edged sword: sepsis, skin cancer risk, and potential Multiple Sclerosis stabilization', UCC Student Medical Journal, 5, p.117. https://doi.org/10.33178/SMJ.2025.1.43en
dc.identifier.doi10.33178/SMJ.2025.1.43en
dc.identifier.endpage117en
dc.identifier.issn2737-7237
dc.identifier.journalabbrevUCC SMJ
dc.identifier.journaltitleUCC Student Medical Journalen
dc.identifier.startpage117en
dc.identifier.urihttps://hdl.handle.net/10468/18120
dc.identifier.volume5
dc.language.isoenen
dc.publisherUCC Medical Research and Technology Societyen
dc.rights© 2025, the Author(s). This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.en
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.sourceBatch uploaden
dc.subjectImmunosuppressionen
dc.subjectSepsisen
dc.subjectSkin cancer risken
dc.subjectMultiple Sclerosis stabilizationen
dc.titleImmunosuppression, a double-edged sword: sepsis, skin cancer risk, and potential Multiple Sclerosis stabilizationen
dc.typeConference itemen
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Immunosuppression,+a+double-edged+sword_+sepsis,+skin+cancer+risk,+and+potential+Multiple+Sclerosis+stabilization.pdf
Size:
415.04 KB
Format:
Adobe Portable Document Format
Description:
Published Version
Download
Collections
UCC Student Medical Journal Vol. 5 (2025)